Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 18/20 | 0.74 |
| ▸ | CYP11B1 | P15538 | 17/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20337616 | 1.00 | CYP11B2 (0.74) | CYP11B2CYP11B1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20337655 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL30777244 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL20337699 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL30777234 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL31411986 | 0.82 | CYP11B2 (0.57) | CYP11B2CYP11B1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20337702 | 0.82 | CYP11B2 (0.57) | CYP11B2CYP11B1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20337729 | 0.81 | CYP11B2 (0.55) | CYP11B2CYP11B1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31411922 | 0.81 | CYP11B2 (0.55) | CYP11B2CYP11B1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31411976 | 0.80 | CYP11B2 (0.66) | CYP11B2CYP11B1CYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562306-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2025-02-26 | — | — | EP | claimed |
| EP-3562306-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2025-02-26 | — | — | EP | disclosed |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | JI XING PHARMACEUTICALS HONG KONG LIMITED (HK) | 2024-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919883-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885ALDH1A1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.